Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Management strategies in hypertrophic cardiomyopathy: influence of age andmorphology
Autore:
McKenna, WJ; Sharma, S; Elliott, PM;
Indirizzi:
St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England St George Hosp London England SW17 0RE iol Sci, London SW17 0RE, England
Titolo Testata:
EUROPEAN HEART JOURNAL SUPPLEMENTS
fascicolo: L, volume: 3, anno: 2001,
pagine: L10 - L14
SICI:
1520-765X(200110)3:L<L10:MSIHCI>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
NONSUSTAINED VENTRICULAR-TACHYCARDIA; PROTEIN-C GENE; SUDDEN-DEATH; OBSTRUCTIVE CARDIOMYOPATHY; CLINICAL IMPROVEMENT; RISK; POPULATION; EXERCISE;
Keywords:
children; hypertrophic cardiomyopathy; hypertrophy; infants; sudden death;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: McKenna, WJ St George Hosp, Sch Med, Dept Cardiol Sci, Cranmer Terrace, London SW17 0RE, England St George Hosp Cranmer Terrace London England SW17 0RE ngland
Citazione:
W.J. McKenna et al., "Management strategies in hypertrophic cardiomyopathy: influence of age andmorphology", EUR H J SUP, 3(L), 2001, pp. L10-L14

Abstract

Management in hypertrophic cardiomyopathy is aimed at improving symptoms and exercise capacity and preventing complications. particularly sudden death. The strategy for management of symptoms is to identify potentially important mechanisms at which treatment can be targeted. Assessment is feasible with non-invasive evaluation. All patients with hypertrophic cardiomyopathyshould undergo risk assessment for sudden death. regardless of their symptomatic. morphological and haemodynamic status. Recent prospective studies have examined five risk markers: family history of sudden death (two or moremembers aged < 45 years). unexplained syncope, non-sustained ventricular tachycardia on Hotter monitoring, abnormal exercise blood pressure response and severe left ventricular hypertrophy (greater than or equal to3 cm). Themajority of patients had none of these risk factors and did not die suddenly. Annual sudden death rates were at least 2% among patients with two or more of these risk markers. which warrants consideration of prophylactic treatment (amiodarone, implantable cardioverter-defibrillator) in such patients. (C) 2001 The European Society of Cardiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 01:24:06